CN103763925A - 高剂量粘膜粘附甲硝唑水基凝胶制剂及其治疗细菌性阴道病的用途 - Google Patents

高剂量粘膜粘附甲硝唑水基凝胶制剂及其治疗细菌性阴道病的用途 Download PDF

Info

Publication number
CN103763925A
CN103763925A CN201280040540.1A CN201280040540A CN103763925A CN 103763925 A CN103763925 A CN 103763925A CN 201280040540 A CN201280040540 A CN 201280040540A CN 103763925 A CN103763925 A CN 103763925A
Authority
CN
China
Prior art keywords
weight
approximately
mtz
gel
mucosal adhesive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280040540.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·T·诺德斯基
K·S·巴拉吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicis Pharmaceutical Corp
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47391265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103763925(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Priority to CN201710998632.5A priority Critical patent/CN107823123A/zh
Publication of CN103763925A publication Critical patent/CN103763925A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280040540.1A 2011-06-28 2012-06-28 高剂量粘膜粘附甲硝唑水基凝胶制剂及其治疗细菌性阴道病的用途 Pending CN103763925A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710998632.5A CN107823123A (zh) 2011-06-28 2012-06-28 高剂量粘膜粘附甲硝唑水基凝胶制剂及其治疗细菌性阴道病的用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161502285P 2011-06-28 2011-06-28
US61/502,285 2011-06-28
US201161508058P 2011-07-14 2011-07-14
US61/508,058 2011-07-14
PCT/US2012/044738 WO2013003646A1 (en) 2011-06-28 2012-06-28 High dosage mucoadhesive metronidazole aqueous-based gel formulations their use to treat bacterial vaginosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710998632.5A Division CN107823123A (zh) 2011-06-28 2012-06-28 高剂量粘膜粘附甲硝唑水基凝胶制剂及其治疗细菌性阴道病的用途

Publications (1)

Publication Number Publication Date
CN103763925A true CN103763925A (zh) 2014-04-30

Family

ID=47391265

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280040540.1A Pending CN103763925A (zh) 2011-06-28 2012-06-28 高剂量粘膜粘附甲硝唑水基凝胶制剂及其治疗细菌性阴道病的用途
CN201710998632.5A Pending CN107823123A (zh) 2011-06-28 2012-06-28 高剂量粘膜粘附甲硝唑水基凝胶制剂及其治疗细菌性阴道病的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710998632.5A Pending CN107823123A (zh) 2011-06-28 2012-06-28 高剂量粘膜粘附甲硝唑水基凝胶制剂及其治疗细菌性阴道病的用途

Country Status (9)

Country Link
US (4) US8946276B2 (https=)
EP (1) EP2725904B1 (https=)
JP (2) JP5986632B2 (https=)
CN (2) CN103763925A (https=)
AU (2) AU2012275292B2 (https=)
BR (1) BR112013033759B1 (https=)
CA (2) CA3054236A1 (https=)
MX (1) MX381271B (https=)
WO (1) WO2013003646A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110693812A (zh) 2012-06-13 2020-01-17 伊沃菲姆股份有限公司 用于增强避孕杀微生物剂有效性的组合物和方法
EP3013368A1 (en) 2013-06-25 2016-05-04 Mission Pharmacal Company Novel formulations for the treatment of vaginal disorders
AU2014368971B2 (en) 2013-12-19 2020-02-06 Evofem, Inc. Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
KR20170052626A (ko) * 2014-09-05 2017-05-12 심바이오믹스 세러퓨틱스 엘엘씨 세균질증 치료에 사용하기 위한 세크니다졸
US11253501B2 (en) 2015-06-01 2022-02-22 Lupin Inc. Secnidazole formulations and use in treating bacterial vaginosis
US10759740B2 (en) 2016-03-24 2020-09-01 Rutgers, The State University Of New Jersey Antibacterial agents
CN110225750A (zh) * 2016-10-04 2019-09-10 伊沃菲姆股份有限公司 细菌性阴道病的治疗和预防方法
SE1750680A1 (en) * 2017-05-30 2018-12-01 Peptonic Medical Ab Composition for treating or preventing climacteric disorders
US20200126094A1 (en) * 2018-10-19 2020-04-23 BioIDC, Inc. Medical research fraud detection system and software
US12280037B2 (en) 2020-09-22 2025-04-22 Evofem Biosciences, Inc. Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012674A1 (en) * 1996-08-02 2002-01-31 Marco Fabrizio Saettone Bioadhesive complexes of polycarbophil and azole antifungal or antiprotozoal drugs
US20090030060A1 (en) * 2004-10-29 2009-01-29 Tolmar, Inc. Intravaginal treatment of vaginal infections with metronidazole compositions
US20100048645A1 (en) * 2005-06-17 2010-02-25 Claire Mallard Solubilizing of metronidazole

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837378A (en) 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
EP0305380B1 (en) 1987-03-20 1991-09-25 Galderma S.A. Novel topical metronidazole formulations
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
CA1337279C (en) 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
EP0537784B1 (en) 1991-10-18 1995-03-01 Dow Corning Corporation Silicone pressure sensitive adhesives having enhanced adhesion to low energy substrates
GB9626513D0 (en) 1996-12-20 1997-02-05 Bioglan Ireland R & D Ltd A pharmaceutical composition
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
WO1998014768A2 (en) 1997-10-06 1998-04-09 Schwartz Sorell L Transdermal chemical monitoring device
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
US7368122B1 (en) 2002-03-08 2008-05-06 Dow Pharmaceutical Sciences Skin cream
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20050186142A1 (en) 2002-10-25 2005-08-25 Foamix Ltd. Kit and composition of imidazole with enhanced bioavailability
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7456207B2 (en) * 2003-09-25 2008-11-25 Teva Pharmaceuticals Usa, Inc. Vaginal pharmaceutical compositions and methods for preparing them
FR2882552B1 (fr) 2005-02-25 2008-12-26 Galderma Sa Gel aqueux de haute stabilite a base de metronidazole et procedes pour leur preparation
WO2007039825A2 (en) 2005-05-09 2007-04-12 Foamix Ltd. Saccharide foamable compositions
WO2007099396A2 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
FR2890560B1 (fr) 2005-09-13 2011-06-24 Galderma Sa Mousses dermatologiques a base de metronidazole et emulsions pour leur preparation
FR2890559B1 (fr) 2005-09-13 2011-06-24 Galderma Sa Mousses dermatologiques a base de metronidazole et emulsions pour la preparation
EP1945227A4 (en) 2005-11-09 2009-09-30 Dow Pharmaceutical Sciences AZITHROMYCIN FOR THE TREATMENT OF GRANULOMATOUS ROSACEA
EA200870153A1 (ru) 2006-01-05 2008-12-30 Драгтек Корпорейшн Композиция и способ ее использования
FR2899475A1 (fr) 2006-04-10 2007-10-12 Galderma Res & Dev Composition pharmaceutique pour le traitement de la rosacee
EP2029106A2 (en) 2006-06-07 2009-03-04 Foamix Ltd. Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof
US20080287513A1 (en) 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080287514A1 (en) 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080287515A1 (en) * 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080312304A1 (en) 2007-06-13 2008-12-18 Jerry Zhang Topical compositions containing metronidazole
US7893097B2 (en) * 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
US20100105750A1 (en) 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
CA2790682C (en) 2010-03-03 2020-11-24 Neocutis Sa Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012674A1 (en) * 1996-08-02 2002-01-31 Marco Fabrizio Saettone Bioadhesive complexes of polycarbophil and azole antifungal or antiprotozoal drugs
US20090030060A1 (en) * 2004-10-29 2009-01-29 Tolmar, Inc. Intravaginal treatment of vaginal infections with metronidazole compositions
US20100048645A1 (en) * 2005-06-17 2010-02-25 Claire Mallard Solubilizing of metronidazole

Also Published As

Publication number Publication date
US8946276B2 (en) 2015-02-03
CA2840571A1 (en) 2013-01-03
JP2014518272A (ja) 2014-07-28
US10596155B2 (en) 2020-03-24
US9198858B2 (en) 2015-12-01
US20160106714A1 (en) 2016-04-21
AU2016200825B2 (en) 2017-10-26
US20130005787A1 (en) 2013-01-03
JP5986632B2 (ja) 2016-09-06
MX2014000066A (es) 2014-05-01
AU2012275292A1 (en) 2014-01-23
WO2013003646A1 (en) 2013-01-03
BR112013033759A8 (pt) 2018-07-31
JP6235087B2 (ja) 2017-11-22
AU2016200825A1 (en) 2016-03-03
BR112013033759B1 (pt) 2021-05-25
AU2012275292B2 (en) 2015-11-12
CA3054236A1 (en) 2013-01-03
US20130005785A1 (en) 2013-01-03
US10238634B2 (en) 2019-03-26
US20190183859A1 (en) 2019-06-20
JP2017014248A (ja) 2017-01-19
MX381271B (es) 2025-03-11
EP2725904B1 (en) 2024-12-11
EP2725904A1 (en) 2014-05-07
CA2840571C (en) 2020-03-24
BR112013033759A2 (pt) 2016-08-16
EP2725904A4 (en) 2014-12-10
CN107823123A (zh) 2018-03-23

Similar Documents

Publication Publication Date Title
US10596155B2 (en) Aqueous-based metronidazole gel formulations
EP1620069B1 (en) Warming and nonirritating lubricant fungicide compositions in the form of a gel
RU2632110C2 (ru) Способ лечения или профилактики бактериального вагиноза
WO2023070102A1 (en) System, product and method for maintaining the vaginal microbiome
AU2013292179B2 (en) Pharmaceutical compositions containing oligomeric lactic acid
US20050080038A1 (en) Vaginal pharmaceutical compositions and methods for preparing them
JP2007077152A (ja) 膣のｐＨを低下させるための組成物および方法
US20060172007A1 (en) Compositions and methods for reducing vaginal pH
US20140206735A1 (en) High dosage topical metronidazole aqueous-based gel formulations and their use to treat rosacea
GB2629661A (en) Compositions and methods for maintaining or enhancing microbial balance of the skin and mucosa

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140430

RJ01 Rejection of invention patent application after publication